Role of dopamine agonists in Parkinson's disease therapy
Journal of Neural Transmission · 2023-06 · 130 (6) · 863-873
DOI: 10.1007/s00702-023-02647-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 11.05.2023. Verfasst von D Woitalla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Katholische Kliniken Der Ruhrhalbinsel, Essen, Germany. D.Woitalla@kkrh.de. Hauptthemen laut MEDLINE: Parkinson Disease, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 104 Literaturangaben.
Abstract (Originalsprache)
Dopamine agonists are an important component of Parkinson's therapy. When weighing up the various therapy options, therapy with levodopa has recently been increasingly preferred due to its stronger efficacy and the ostensibly lower rate of side effects. The advantage of the lower incidence of motor complications during therapy with dopamine agonists was neglected. The occurrence of side effects can be explained by the different receptor affinity to the individual dopaminergic and non-dopaminergic receptors of the individual dopamine agonists. However, the different affinity to individual receptors also explains the different effect on individual Parkinson symptoms and can, therefore, contribute to a targeted use of the different dopamine agonists. Since comparative studies on the differential effect of dopamine agonists have only been conducted for individual substances, empirical knowledge of the differential effect is of great importance. Therefore, the guidelines for the treatment of Parkinson's disease do not consider the differential effect of the dopamine agonists. The historical consideration of dopamine agonists within Parkinson's therapy deserves special attention to be able to classify the current discussion about the significance of dopamine agonists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Katholische Kliniken Der Ruhrhalbinsel, Essen, Germany. D.Woitalla@kkrh.de.
- Department of Neurology, Universitätsklinikum Hamburg, Hamburg, Germany.
- Department of Neurology, Klinikum Vest, Recklinghausen, Germany.
- Department of Neurology, Medizinische Hochschule Hannover, Hannover, Germany.
- Department of Neurology Parkinson-Klinik Ortenau, Wolfach, Germany.
- Department of Neurology, Alexianer St. Joseph Krankenhaus, Berlin, Germany.
Zitieren
APA
Woitalla, D., Buhmann, C., Hilker-Roggendorf, R., Höglinger, G., Koschel, J., Müller, T., & Weise, D. (2023). Role of dopamine agonists in Parkinson's disease therapy. Journal of Neural Transmission, 130(6), 863-873. https://doi.org/10.1007/s00702-023-02647-0
Vancouver
Woitalla D, Buhmann C, Hilker-Roggendorf R, Höglinger G, Koschel J, Müller T, et al. Role of dopamine agonists in Parkinson's disease therapy. Journal of Neural Transmission. 2023;130(6):863-873. doi:10.1007/s00702-023-02647-0
BibTeX
@article{Woitalla2023,
author = {Woitalla, D and Buhmann, C and Hilker-Roggendorf, R and Höglinger, G and Koschel, J and Müller, T and Weise, D},
title = {Role of dopamine agonists in Parkinson's disease therapy},
journal = {Journal of Neural Transmission},
year = {2023},
volume = {130},
number = {6},
pages = {863--873},
doi = {10.1007/s00702-023-02647-0}
}
EUVIMED